According to Alnylam Pharmaceuticals
's latest financial reports the company has a price-to-book ratio of -86.5.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | N/A | -100% |
2023-12-31 | -109 | -41.09% |
2022-12-31 | -185 | -635.91% |
2021-12-31 | 34.5 | 132.06% |
2020-12-31 | 14.9 | 65.45% |
2019-12-31 | 8.98 | 58.51% |
2018-12-31 | 5.67 | -20.57% |
2017-12-31 | 7.13 | 104.3% |
2016-12-31 | 3.49 | -44.88% |
2015-12-31 | 6.33 | -20.81% |
2014-12-31 | 8.00 | -47.24% |
2013-12-31 | 15.2 | 112.15% |
2012-12-31 | 7.15 | 142.14% |
2011-12-31 | 2.95 | 11.85% |
2010-12-31 | 2.64 | -36.3% |
2009-12-31 | 4.14 | -18.25% |
2008-12-31 | 5.07 | -14.89% |
2007-12-31 | 5.95 | 51.05% |
2006-12-31 | 3.94 | -5.49% |
2005-12-31 | 4.17 | 33.58% |
2004-12-31 | 3.12 | |
2003-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Novartis NVS | 5.17 | -105.97% | ๐จ๐ญ Switzerland |
Sanofi SNY | 1.46 | -101.69% | ๐ซ๐ท France |
Regeneron Pharmaceuticals REGN | 3.95 | -104.56% | ๐บ๐ธ USA |
Sarepta Therapeutics
SRPT | 12.2 | -114.14% | ๐บ๐ธ USA |
Regulus Therapeutics RGLS | 1.38 | -101.59% | ๐บ๐ธ USA |
OPKO Health
OPK | 0.7844 | -100.91% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | 2.54 | -102.93% | ๐ฎ๐ฑ Israel |
Arrowhead Pharmaceuticals
ARWR | 5.73 | -106.62% | ๐บ๐ธ USA |